-
Product Insights
NewNet Present Value Model: Calliditas Therapeutics AB’s Setanaxib
Empower your strategies with our Net Present Value Model: Calliditas Therapeutics AB's Setanaxib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MB-103 in Brain Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MB-103 in Brain Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MB-103 in Brain Cancer Drug Details: MB-103 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MB-103 in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MB-103 in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MB-103 in Glioblastoma Multiforme (GBM) Drug Details: MB-103 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BAT-6026 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BAT-6026 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BAT-6026 in Solid Tumor Drug Details: BAT-6026 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Talazoparib in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Talazoparib in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Talazoparib in Metastatic Breast Cancer Drug Details: Talazoparib (Talzenna, Tarzena) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MB-207 in X-Linked SCID
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MB-207 in X-Linked SCID report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MB-207 in X-Linked SCID Drug Details: MB-207 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab in Carcinoma of Unknown Primary (Occult Primary Tumor/Cancer of Unknown Primary)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Carcinoma of Unknown Primary (Occult Primary Tumor/Cancer of Unknown Primary) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab in Carcinoma...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MB-105 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MB-105 in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MB-105 in Pancreatic Cancer Drug Details: MB-105 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MB-106 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MB-106 in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MB-106 in Mantle Cell Lymphoma Drug Details: MB-106 is under investigation...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MB-106 in Burkitt Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MB-106 in Burkitt Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MB-106 in Burkitt Lymphoma Drug Details: MB-106 is under investigation for the...